WO2018041248A1 - Inhibiteur sélectif de bcl -2, sa préparation et son utilisation - Google Patents

Inhibiteur sélectif de bcl -2, sa préparation et son utilisation Download PDF

Info

Publication number
WO2018041248A1
WO2018041248A1 PCT/CN2017/100226 CN2017100226W WO2018041248A1 WO 2018041248 A1 WO2018041248 A1 WO 2018041248A1 CN 2017100226 W CN2017100226 W CN 2017100226W WO 2018041248 A1 WO2018041248 A1 WO 2018041248A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
group
pyridin
etoac
pyrrolo
Prior art date
Application number
PCT/CN2017/100226
Other languages
English (en)
Chinese (zh)
Inventor
王虎庭
朱岩
商现星
张久庆
胡远东
何伟男
张慧
张淑远
侯登
刘琦超
彭勇
韩永信
Original Assignee
北京赛林泰医药技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610800391.4A external-priority patent/CN107793412A/zh
Priority claimed from CN201710604198.8A external-priority patent/CN109293656A/zh
Application filed by 北京赛林泰医药技术有限公司 filed Critical 北京赛林泰医药技术有限公司
Priority to CN201780053177.XA priority Critical patent/CN109641897B/zh
Publication of WO2018041248A1 publication Critical patent/WO2018041248A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

L'invention concerne un composé représenté par la formule (I). Le composé inhibe sélectivement une activité de protéine anti-apoptotique de Bcl -2, et peut traiter une maladie auto-immune ou un cancer.
PCT/CN2017/100226 2016-09-01 2017-09-01 Inhibiteur sélectif de bcl -2, sa préparation et son utilisation WO2018041248A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780053177.XA CN109641897B (zh) 2016-09-01 2017-09-01 Bcl-2选择性抑制剂及其制备和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610800391.4A CN107793412A (zh) 2016-09-01 2016-09-01 Bcl‑2选择性抑制剂及其制备和用途
CN201610800391.4 2016-09-01
CN201710604198.8A CN109293656A (zh) 2017-07-24 2017-07-24 Bcl-2选择性抑制剂及其制备和用途
CN201710604198.8 2017-07-24

Publications (1)

Publication Number Publication Date
WO2018041248A1 true WO2018041248A1 (fr) 2018-03-08

Family

ID=61300127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/100226 WO2018041248A1 (fr) 2016-09-01 2017-09-01 Inhibiteur sélectif de bcl -2, sa préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN109641897B (fr)
WO (1) WO2018041248A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019210828A1 (fr) 2018-04-29 2019-11-07 Beigene, Ltd. Inhibiteurs de bcl-2
CN111747949A (zh) * 2019-03-29 2020-10-09 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
EP3565815A4 (fr) * 2017-01-07 2020-10-28 Shanghai Fochon Pharmaceutical Co., Ltd. Composés en tant qu'agents induisant l'apoptose sélective de bcl-2
US11091478B2 (en) 2017-04-18 2021-08-17 Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
CN114008035A (zh) * 2019-06-14 2022-02-01 北京盛诺基医药科技股份有限公司 一种shp2磷酸酶变构抑制剂
WO2022028353A1 (fr) 2020-08-06 2022-02-10 北京诺诚健华医药科技有限公司 Composé hétérocyclique en tant qu'inhibiteur de bcl-2
JP7473545B2 (ja) 2018-10-29 2024-04-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド トリフルオロメチル置換スルファミド系選択的ｂｃｌ－２阻害剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448959A (zh) * 2009-05-26 2012-05-09 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN105026394A (zh) * 2013-03-14 2015-11-04 艾伯维公司 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448959A (zh) * 2009-05-26 2012-05-09 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN105026394A (zh) * 2013-03-14 2015-11-04 艾伯维公司 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREW J SOUERS ET AL.: "ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets", NATURE MEDICINE, vol. 19, no. 2, 28 February 2013 (2013-02-28), pages 202 - 208, XP055325000, Retrieved from the Internet <URL:doi:10.1038/nm.3048> *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815A4 (fr) * 2017-01-07 2020-10-28 Shanghai Fochon Pharmaceutical Co., Ltd. Composés en tant qu'agents induisant l'apoptose sélective de bcl-2
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
US11091478B2 (en) 2017-04-18 2021-08-17 Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
WO2019210828A1 (fr) 2018-04-29 2019-11-07 Beigene, Ltd. Inhibiteurs de bcl-2
JP7473545B2 (ja) 2018-10-29 2024-04-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド トリフルオロメチル置換スルファミド系選択的ｂｃｌ－２阻害剤
CN111747949A (zh) * 2019-03-29 2020-10-09 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
CN114008035A (zh) * 2019-06-14 2022-02-01 北京盛诺基医药科技股份有限公司 一种shp2磷酸酶变构抑制剂
WO2022028353A1 (fr) 2020-08-06 2022-02-10 北京诺诚健华医药科技有限公司 Composé hétérocyclique en tant qu'inhibiteur de bcl-2

Also Published As

Publication number Publication date
CN109641897A (zh) 2019-04-16
CN109641897B (zh) 2021-12-07

Similar Documents

Publication Publication Date Title
WO2018041248A1 (fr) Inhibiteur sélectif de bcl -2, sa préparation et son utilisation
CN109195602B (zh) 用作免疫调节剂的对称或半对称化合物
RU2674701C2 (ru) Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы
JP6777652B2 (ja) 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物
WO2021088945A1 (fr) Composé utilisé comme inhibiteur de shp2 et son utilisation
RU2637936C2 (ru) Ингибиторы активности киназы lrrk2
JP6080227B2 (ja) ロイコトリエン生成を阻害するためのベンゾジオキサン
CN111886219A (zh) 免疫抑制剂及其制备方法和在药学上的应用
TW201910328A (zh) 雜環化合物
EA031262B1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
WO2021258010A1 (fr) Composés oxime utiles comme activateurs de lymphocytes t
WO2010058846A1 (fr) 4,6-diaminonicotinamide
WO2019101086A1 (fr) Inhibiteur de ssao/vap-1 halo-allylamine et son utilisation
TWI452044B (zh) 嗎啉衍生物
KR20140138851A (ko) 류코트리엔 생성 억제를 위해 기타 활성제와 병용된 벤조디옥산
WO2022100623A1 (fr) Composés thiophène hétérocycliques substitués par azote et leur utilisation
TW201602105A (zh) 雜環化合物
WO2020233641A1 (fr) Composé utilisé comme inhibiteur de kinase ret et son utilisation
WO2021190417A1 (fr) Nouvel inhibiteur aminopyrimidine d&#39;egfr
KR20090114439A (ko) 아실구아니딘 유도체
KR102354082B1 (ko) 기생충 질환, 예컨대 리슈마니아증을 치료하기 위한 원충 프로테아솜 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체
WO2018127184A1 (fr) Inhibiteur de la kinase du lymphome anaplasique, son procédé de préparation et son utilisation
TW201348213A (zh) 喹唑啉二酮衍生物
WO2018228475A1 (fr) Inhibiteur de syk et procédé d&#39;utilisation correspondant
WO2022242767A1 (fr) Composé spiro et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17845550

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17845550

Country of ref document: EP

Kind code of ref document: A1